Seres Therapeutics has presented interim results from an ongoing Phase II trial which has sent company stock spiralling downward, as …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

